Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 10/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2329799 | 0.93 | CNR2 (0.54) | POLBCNR2ALDH1A1MEN1KMT2A | |
| SCHEMBL2325902 | 0.91 | POLB (0.52) | POLBCNR2CTSLCTSBCTSS | |
| SCHEMBL2328785 | 0.89 | POLB (0.49) | POLBCNR2CTSLCTSBCTSS | |
| SCHEMBL2329062 | 0.89 | POLB (0.51) | POLBCNR2CTSLCTSBCTSS | |
| SCHEMBL2326606 | 0.83 | POLB (0.52) | POLBCNR2CTSLCTSBCTSS | |
| SCHEMBL2334144 | 0.83 | POLB (0.52) | POLBCNR2L3MBTL1 | |
| SCHEMBL2334148 | 0.83 | POLB (0.52) | POLBCNR2L3MBTL1 | |
| SCHEMBL2327345 | 0.82 | CYP26A1 (0.50) | CTSLMEN1KMT2A | |
| SCHEMBL13583738 | 0.80 | MAPT (0.46) | POLBALDH1A1KMT2AHPGDL3MBTL1 | |
| SCHEMBL2322718 | 0.79 | CNR2 (0.49) | POLBCNR2CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356979-B1 | ANTI-WRINKLE AGENTS | POLA CHEM IND INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| EP-3173063-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2017-05-31 | — | — | EP | disclosed |
| US-8835498-B2 | Anti-wrinkle agents | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| EP-2356979-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | GLA, H1-4, H1-3 | POLB 1044/4885CNR2 1779/4885CTSL 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.